Thromb Haemost 2002; 87(03): 536-537
DOI: 10.1055/s-0037-1613036
Letters to the Editor
Schattauer GmbH

Enoxaparin Sodium Improves Pregnancy Outcome in Aspirin-resistant Antiphospholipid/Antiprotein Antibody Syndromes

Jean-Christophe Gris
1   Laboratoires d’Hématologie, CHU, Nîmes et
2   U.F.R. des Sciences Pharmaceutiques et Biologiques, Montpellier
,
Jean-Pierre Balducchi
3   Département de Médecine Interne et
,
Isabelle Quéré
1   Laboratoires d’Hématologie, CHU, Nîmes et
,
Méderic Hoffet
4   Département de Gynécologie et Obstétrique, CHU, Nîmes, France
,
Pierre Marès
4   Département de Gynécologie et Obstétrique, CHU, Nîmes, France
› Author Affiliations
Further Information

Publication History

Received 02 August 2001

Accepted after revision 12 December 2001

Publication Date:
14 December 2017 (online)

 

 
  • References

  • 1 Kutteh WH. Antiphopholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol 1996; 174: 1584-9.
  • 2 Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies. . Br Med J 1997; 314: 253-7.
  • 3 Pattison NS, Chamley LW, Birdsall M, Zanderigo AM, Liddell HS, McDougall J. Does aspirin have a role in improving pregnancy outcome for women with the antiphospholipid syndrome? A randomized controlled study. Am J Obstet Gynecol 2000; 183: 1008-12.
  • 4 Brenner B, Hoffman R, Blumenfeld Z, Weiner Z, Younis JS. Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin. Thromb Haemost 2000; 83: 693-7.
  • 5 Gris JC, Quéré I, Sanmarco M, Boutière B, Mercier E, Amiral J, Hubert AM, Ripart-Neveu S, Hoffet M, Tailland L, Rousseau O, Monpeyroux F, Dauzat M, Sampol J, Daurès JP, Berlan J, Marès P. Antiphospholipid and antiprotein syndromes in non-thrombotic, non-autoimmune women with unexplained recurrent primary early foetal loss. NOHA4. Thromb Haemost 2000; 84: 228-36.
  • 6 Casele HL, Laifer SA, Woelkers DA, Venkataramanan R. Changes in the pharmacokinetics of the low-molecular weight heparin enoxaparin sodium during pregnancy. Am J Obstet Gynecol 1999; 181: 1113-7.
  • 7 Meli G, Spiro TE, Olsson CG, Abildgaard U, Davidson BL, Eldor A, Elias D, Grigg A, Musset D, Rodgers GM, Trowbridge AA, Yusen RD, Zawilska K. The Enoxaparin Clinical Trial Group. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann Intern Med 2001; 134: 191-202.